Federated Hermes, Inc. Exelixis, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 223,543 shares of EXEL stock, worth $8.09 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

223,543

Previous 227,909 1.92%

Holding current value

$8.09 Million

Previous $5.12 Million 13.26%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$21.96 - $27.6 $95,877 - $120,501	-4,366 Reduced 1.92%	223,543 $5.8 Million
Q2 2024 Aug 08, 2024	BUY	$20.34 - $23.73 $47,453 - $55,362	2,333 Added 1.03%	227,909 $5.12 Million
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $673,899 - $799,525	33,411 Added 17.39%	225,576 $5.35 Million
Q4 2023 Jan 31, 2024	BUY	$19.25 - $24.13 $233,271 - $292,407	12,118 Added 6.73%	192,165 $4.61 Million
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $476,304 - $568,863	25,016 Added 16.14%	180,047 $3.93 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $76,059 - $85,729	-4,186 Reduced 2.63%	155,031 $2.96 Million
Q1 2023 May 08, 2023	SELL	$16.3 - $19.41 $809,621 - $964,094	-49,670 Reduced 23.78%	159,217 $3.09 Million
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $141,910 - $164,961	-9,486 Reduced 4.34%	208,887 $3.35 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $128,701 - $182,792	-8,208 Reduced 3.62%	218,373 $3.42 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $1.84 Million - $2.44 Million	-105,499 Reduced 31.77%	226,581 $4.72 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $3.71 Million - $4.94 Million	217,714 Added 190.37%	332,080 $7.53 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $691,336 - $954,952	43,645 Added 61.71%	114,366 $2.09 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $90,937 - $117,940	-5,579 Reduced 7.31%	70,721 $1.5 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $93,716 - $133,448	-5,221 Reduced 6.4%	76,300 $1.39 Million
Q1 2021 May 13, 2021	SELL	$20.53 - $25.22 $397,111 - $487,830	-19,343 Reduced 19.18%	81,521 $1.84 Million
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $142,393 - $192,026	-7,743 Reduced 7.13%	100,864 $2.02 Million
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $238,862 - $311,318	-11,556 Reduced 9.62%	108,607 $2.66 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $280,560 - $467,373	17,045 Added 16.53%	120,163 $2.85 Million
Q1 2020 May 13, 2020	SELL	$14.46 - $21.8 $81,323 - $122,603	-5,624 Reduced 5.17%	103,118 $1.78 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $2.37 Million - $2.95 Million	-156,369 Reduced 58.98%	108,742 $1.92 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $75,475 - $96,692	-4,269 Reduced 1.58%	265,111 $4.69 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $519,590 - $679,338	-27,448 Reduced 9.25%	269,380 $5.76 Million
Q1 2019 May 10, 2019	BUY	$19.6 - $24.76 $3.32 Million - $4.2 Million	169,471 Added 133.07%	296,828 $7.07 Million
Q4 2018 Feb 13, 2019	SELL	$13.65 - $21.8 $198,566 - $317,124	-14,547 Reduced 10.25%	127,357 $2.51 Million
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $1.81 Million - $2.55 Million	-113,804 Reduced 44.51%	141,904 $2.52 Million
Q2 2018 Aug 10, 2018	BUY	$18.56 - $22.45 $2.07 Million - $2.5 Million	111,496 Added 77.31%	255,708 $5.5 Million
Q1 2018 May 09, 2018	BUY	$22.15 - $31.89 $1.68 Million - $2.42 Million	76,001 Added 111.42%	144,212 $3.19 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $869,929 - $1.11 Million	-35,903 Reduced 34.48%	68,211 $0
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $2.43 Million - $3.04 Million	104,114	104,114 $2.52 Million

Others Institutions Holding EXEL

# of Institutions

507

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Exelixis, Inc. Transaction History